{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T20:59:21Z","timestamp":1765486761019,"version":"3.40.5"},"reference-count":40,"publisher":"Archives of Endocrinology and Metabolism","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,5,25]]},"DOI":"10.20945\/2359-3997000000481","type":"journal-article","created":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T12:28:00Z","timestamp":1653568080000},"source":"Crossref","is-referenced-by-count":3,"title":["Efficacy of cabergoline add-on therapy in patients with acromegaly resistance to somatostatin analogs treatment and the review of literature"],"prefix":"10.20945","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8468-9196","authenticated-orcid":false,"given":"Muhammed","family":"Kizilgul","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5478-3192","authenticated-orcid":false,"given":"Hakan","family":"Duger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8013-230X","authenticated-orcid":false,"given":"Narin Imga","family":"Nasiroglu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5581-4886","authenticated-orcid":false,"given":"Erkam","family":"Sencar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8375-7409","authenticated-orcid":false,"given":"Sema","family":"Hepsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1662-3363","authenticated-orcid":false,"given":"Pinar","family":"Akhanli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6388-7505","authenticated-orcid":false,"given":"Dilek","family":"Berker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4455-7276","authenticated-orcid":false,"given":"Erman","family":"Cakal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4957-9856","authenticated-orcid":false,"given":"Hayri","family":"Bostan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0810-5224","authenticated-orcid":false,"given":"Bekir","family":"Ucan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"8510","reference":[{"issue":"11","key":"key20220526082755_B1","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.1210\/jc.2014-2700","article-title":"Acromegaly: an endocrine society clinical practice guideline","volume":"99","author":"Katznelson","year":"2014","unstructured":"Katznelson L, Laws ER, Melmed S, Molitch ME, Murad MH, Utz A, et al. Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(11):3933-51.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"key20220526082755_B2","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s11154-020-09588-z","article-title":"Multidisciplinary management of acromegaly: A consensus","volume":"21","author":"Giustina","year":"2020","unstructured":"Giustina A, Barkhoudarian G, Beckers A, Ben-Shlomo A, Biermasz N, Biller B, et al. Multidisciplinary management of acromegaly: A consensus. Rev Endocr Metab Disord. 2020;21(4):667-78.","journal-title":"Rev Endocr Metab Disord"},{"issue":"5","key":"key20220526082755_B3","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1210\/jc.2010-2443","article-title":"Place of cabergoline in acromegaly: a meta-analysis","volume":"96","author":"Sandret","year":"2011","unstructured":"Sandret L, Maison P, Chanson P. Place of cabergoline in acromegaly: a meta-analysis. J Clin Endocrinol Metab. 2011;96(5):1327-35.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"key20220526082755_B4","first-page":"717","article-title":"Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human","volume":"19","author":"Giustina","year":"1998","unstructured":"Giustina A, Veldhuis JD. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr Rev. 1998;19(6):717-97.","journal-title":"Endocr Rev"},{"issue":"2","key":"key20220526082755_B5","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1210\/jcem-38-2-200","article-title":"Inhibitory effect of dopaminergic stimulation on GH release in acromegaly","volume":"38","author":"Chiodini","year":"1974","unstructured":"Chiodini PG, Liuzzi A, Botalla L, Cremascoli G, Silvestrini F. Inhibitory effect of dopaminergic stimulation on GH release in acromegaly. J Clin Endocrinol Metab. 1974;38(2):200-6.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"key20220526082755_B6","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1210\/jcem-55-4-734","article-title":"In vitro effect of dopamine on growth hormone (GH) release from human GH-secreting pituitary adenomas","volume":"55","author":"Spada","year":"1982","unstructured":"Spada A, Sartorio A, Bassetti M, Pezzo G, Giannattasio G. In vitro effect of dopamine on growth hormone (GH) release from human GH-secreting pituitary adenomas. J Clin Endocrinol Metab. 1982;55(4):734-40.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"key20220526082755_B7","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1210\/jcem-55-3-589","article-title":"Evidence of dopamine receptors in human growth hormone (GH)-secreting adenomas with concomitant study of dopamine inhibition of GH secretion in a perifusion system","volume":"55","author":"Bression","year":"1982","unstructured":"Bression D, Brandi AM, Nousbaum A, Le Dafniet M, Racadot J, Peillon F. Evidence of dopamine receptors in human growth hormone (GH)-secreting adenomas with concomitant study of dopamine inhibition of GH secretion in a perifusion system. J Clin Endocrinol Metab. 1982;55(3):589-93.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"key20220526082755_B8","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1385\/ENDO:14:3:329","article-title":"Dopamine D2 receptor gene expression in human adenohypophysial adenomas","volume":"14","author":"Stefaneanu","year":"2001","unstructured":"Stefaneanu L, Kovacs K, Horvath E, Buchfelder M, Fahlbusch R, Lancranjan L. Dopamine D2 receptor gene expression in human adenohypophysial adenomas. Endocrine. 2001;14(3):329-36.","journal-title":"Endocrine"},{"issue":"9","key":"key20220526082755_B9","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/s41574-018-0058-5","article-title":"A Consensus Statement on acromegaly therapeutic outcomes","volume":"14","author":"Melmed","year":"2018","unstructured":"Melmed S, Bronstein MD, Chanson P, Klibanski A, Casanueva FF, Wass JAH, et al. A Consensus Statement on acromegaly therapeutic outcomes. Nat Rev Endocrinol. 2018;14(9):552-61.","journal-title":"Nat Rev Endocrinol"},{"issue":"5463","key":"key20220526082755_B10","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1126\/science.288.5463.154","article-title":"Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity","volume":"288","author":"Rocheville","year":"2000","unstructured":"Rocheville M, Lange DC, Kumar U, Patel SC, Patel RC, Patel YC. Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science. 2000;288(5463):154-7.","journal-title":"Science"},{"issue":"2","key":"key20220526082755_B11","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1210\/jcem.83.2.4556","article-title":"Cabergoline in the treatment of acromegaly: a study in 64 patients","volume":"83","author":"Abs","year":"1998","unstructured":"Abs R, Verhelst J, Maiter D, Van Acker K, Nobels F, Coolens JL, et al. Cabergoline in the treatment of acromegaly: a study in 64 patients. J Clin Endocrinol Metab. 1998;83(2):374-8.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"key20220526082755_B12","doi-asserted-by":"crossref","first-page":"51","DOI":"10.4158\/EP-2020-0398","article-title":"The Prevalence of Cancer and Its Relation to Disease Activity in Patients With Acromegaly: Two Centers\u2019 Experience","volume":"27","author":"Ucan","year":"2021","unstructured":"Ucan B, Kizilgul M, Karci AC, Duger H, Erkam Sencar M, Imga NN, et al. The Prevalence of Cancer and Its Relation to Disease Activity in Patients With Acromegaly: Two Centers\u2019 Experience. Endocr Pract. 2021;27(1):51-5.","journal-title":"Endocr Pract"},{"issue":"4","key":"key20220526082755_B13","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1507\/endocrj.EJ18-0502","article-title":"The effect of disease activity on thyroid nodules in patients with acromegaly","volume":"66","author":"Kan","year":"2019","unstructured":"Kan S, Kizilgul M, Celik B, Beysel S, Caliskan M, Apaydin M, et al. The effect of disease activity on thyroid nodules in patients with acromegaly. Endocr J. 2019;66(4):301-7.","journal-title":"Endocr J"},{"issue":"1","key":"key20220526082755_B14","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41572-019-0071-6","article-title":"Acromegaly","volume":"5","author":"Colao","year":"2019","unstructured":"Colao A, Grasso LFS, Giustina A, Melmed S, Chanson P, Pereira AM, et al. Acromegaly. Nat Rev Dis Prim. 2019;5(1):20.","journal-title":"Nat Rev Dis Prim"},{"issue":"4","key":"key20220526082755_B15","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1210\/jc.2004-2009","article-title":"Relationship between disease-related morbidity and biochemical markers of activity in patients with acromegaly","volume":"90","author":"Puder","year":"2005","unstructured":"Puder JJ, Nilavar S, Post KD, Freda PU. Relationship between disease-related morbidity and biochemical markers of activity in patients with acromegaly. J Clin Endocrinol Metab. 2005;90(4):1972-8.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"key20220526082755_B16","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1210\/jc.2003-032041","article-title":"Determinants of survival in treated acromegaly in a single center: predictive value of serial insulin-like growth factor I measurements","volume":"89","author":"Biermasz","year":"2004","unstructured":"Biermasz NR, Dekker FW, Pereira AM, van Thiel SW, Schutte PJ, van Dulken H, et al. Determinants of survival in treated acromegaly in a single center: predictive value of serial insulin-like growth factor I measurements. J Clin Endocrinol Metab. 2004;89(6):2789-96.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"key20220526082755_B17","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1210\/jc.2003-031199","article-title":"Factors influencing mortality in acromegaly","volume":"89","author":"Holdaway","year":"2004","unstructured":"Holdaway IM, Rajasoorya RC, Gamble GD. Factors influencing mortality in acromegaly. J Clin Endocrinol Metab. 2004;89(2):667-74.","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"key20220526082755_B18","doi-asserted-by":"crossref","first-page":"3190","DOI":"10.1210\/jc.2013-1036","article-title":"Endoscopic vs microsurgical transsphenoidal surgery for acromegaly: outcomes in a concurrent series of patients using modern criteria for remission","volume":"98","author":"Starke","year":"2013","unstructured":"Starke RM, Raper DMS, Payne SC, Vance ML, Oldfield EH, Jane JA. Endoscopic vs microsurgical transsphenoidal surgery for acromegaly: outcomes in a concurrent series of patients using modern criteria for remission. J Clin Endocrinol Metab. 2013;98(8):3190-8.","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"key20220526082755_B19","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1210\/jc.2011-0554","article-title":"Endoscopic transsphenoidal surgery for acromegaly: remission using modern criteria, complications, and predictors of outcome","volume":"96","author":"Jane","year":"2011","unstructured":"Jane JA, Starke RM, Elzoghby MA, Reames DL, Payne SC, Thorner MO, et al. Endoscopic transsphenoidal surgery for acromegaly: remission using modern criteria, complications, and predictors of outcome. J Clin Endocrinol Metab. 2011;96(9):2732-40.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"key20220526082755_B20","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1210\/jc.2008-1371","article-title":"The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly","volume":"94","author":"Carmichael","year":"2009","unstructured":"Carmichael JD, Bonert VS, Mirocha JM, Melmed S. The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly. J Clin Endocrinol Metab. 2009;94(2):523-7.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3-4","key":"key20220526082755_B21","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1159\/000095536","article-title":"Somatostatin and Dopamine-Somatostatin Multiple Ligands Directed towards Somatostatin and Dopamine Receptors in Pituitary Adenomas","volume":"83","author":"Saveanu","year":"2006","unstructured":"Saveanu A, Gunz G, Guillen S, Dufour H, Culler MD, Jaquet P. Somatostatin and Dopamine-Somatostatin Multiple Ligands Directed towards Somatostatin and Dopamine Receptors in Pituitary Adenomas. Neuroendocrinology. 2006;83(3-4):258-63.","journal-title":"Neuroendocrinology"},{"issue":"4","key":"key20220526082755_B22","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1210\/jc.2007-1358","article-title":"Correlation of in Vitro and in Vivo Somatotropic Adenoma Responsiveness to Somatostatin Analogs and Dopamine Agonists with Immunohistochemical Evaluation of Somatostatin and Dopamine Receptors and Electron Microscopy","volume":"93","author":"Ferone","year":"2008","unstructured":"Ferone D, de Herder WW, Pivonello R, Kros JM, van Koetsveld PM, de Jong T, et al. Correlation of in Vitro and in Vivo Somatotropic Adenoma Responsiveness to Somatostatin Analogs and Dopamine Agonists with Immunohistochemical Evaluation of Somatostatin and Dopamine Receptors and Electron Microscopy. J Clin Endocrinol Metab. 2008;93(4):1412-7.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"key20220526082755_B23","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1210\/endo.140.1.6450","article-title":"Differential Actions of the Dopamine Agonist Bromocriptine on Growth of SMtTW Tumors Exhibiting a Prolactin and\/or a Somatotroph Cell Phenotype: Relation to Dopamine D2 Receptor Expression*","volume":"140","author":"Trouillas","year":"1999","unstructured":"Trouillas J, Chevallier P, Remy C, Rajas F, Cohen R, Calle A, et al. Differential Actions of the Dopamine Agonist Bromocriptine on Growth of SMtTW Tumors Exhibiting a Prolactin and\/or a Somatotroph Cell Phenotype: Relation to Dopamine D2 Receptor Expression*. Endocrinology. 1999;140(1):13-21.","journal-title":"Endocrinology"},{"issue":"1","key":"key20220526082755_B24","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1023\/B:PITU.0000044630.83354.f0","article-title":"Cabergoline therapy of growth hormone & growth hormone\/prolactin secreting pituitary tumors","volume":"7","author":"Freda","year":"2004","unstructured":"Freda PU, Reyes CM, Nuruzzaman AT, Sundeen RE, Khandji AG, Post KD. Cabergoline therapy of growth hormone & growth hormone\/prolactin secreting pituitary tumors. Pituitary. 2004;7(1):21-30.","journal-title":"Pituitary"},{"issue":"2","key":"key20220526082755_B25","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s11102-010-0272-1","article-title":"Role of the addition of cabergoline to the management of acromegalic patients resistant to longterm treatment with octreotide LAR","volume":"14","author":"Vilar","year":"2011","unstructured":"Vilar L, Azevedo MF, Naves LA, Casulari LA, Albuquerque JL, Montenegro RM, et al. Role of the addition of cabergoline to the management of acromegalic patients resistant to longterm treatment with octreotide LAR. Pituitary. 2011;14(2):148-56.","journal-title":"Pituitary"},{"issue":"1","key":"key20220526082755_B26","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s11102-016-0782-6","article-title":"Cabergoline in acromegaly","volume":"20","author":"Kuhn","year":"2017","unstructured":"Kuhn E, Chanson P. Cabergoline in acromegaly. Pituitary. 2017;20(1):121-8.","journal-title":"Pituitary"},{"issue":"5","key":"key20220526082755_B27","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/cen.12207","article-title":"Control of growth hormone and IGF1 in patients with acromegaly in the UK: responses to medical treatment with somatostatin analogues and dopamine agonists","volume":"79","author":"Howlett","year":"2013","unstructured":"Howlett TA, Willis D, Walker G, Wass JAH, Trainer PJ. Control of growth hormone and IGF1 in patients with acromegaly in the UK: responses to medical treatment with somatostatin analogues and dopamine agonists. Clin Endocrinol (Oxf). 2013;79(5):689-99.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"01","key":"key20220526082755_B28","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1055\/s-0034-1389987","article-title":"Treatment Outcome Results from the Bulgarian Acromegaly Database: Adjuvant Dopamine Agonist Therapy is Efficient in Less than One Fifth of Non-irradiated Patients","volume":"123","author":"Vandeva","year":"2015","unstructured":"Vandeva S, Elenkova A, Natchev E, Kirilov G, Tcharaktchiev D, Yaneva M, et al. Treatment Outcome Results from the Bulgarian Acromegaly Database: Adjuvant Dopamine Agonist Therapy is Efficient in Less than One Fifth of Non-irradiated Patients. Exp Clin Endocrinol Diabetes. 2015;123(01):66-71.","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"9","key":"key20220526082755_B29","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1055\/a-1274-1276","article-title":"Effectiveness of Cabergoline Treatment in Patients with Acromegaly Uncontrolled with SSAs: Experience of a Single Tertiary Center","volume":"129","author":"Sahin","year":"2020","unstructured":"Sahin S, Fidan MC, Korkmaz OP, Durcan E, Ozkaya HM, Kadioglu P. Effectiveness of Cabergoline Treatment in Patients with Acromegaly Uncontrolled with SSAs: Experience of a Single Tertiary Center. Exp Clin Endocrinol Diabetes. 2020;129(9):644-50.","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"3","key":"key20220526082755_B30","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1385\/ENDO:20:3:299","article-title":"Comparison of Efficacy and Tolerability of Somatostatin Analogs and Other Therapies for Acromegaly","volume":"20","author":"Burt","year":"2003","unstructured":"Burt MG, Ho KKY. Comparison of Efficacy and Tolerability of Somatostatin Analogs and Other Therapies for Acromegaly. Endocrine. 2003;20(3):299-306.","journal-title":"Endocrine"},{"issue":"2","key":"key20220526082755_B31","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1159\/000317314","article-title":"Short- and Long-Term Efficacy of Combined Cabergoline and Octreotide Treatment in Controlling IGF-I Levels in Acromegaly","volume":"92","author":"Mattar","year":"2010","unstructured":"Mattar P, Alves Martins MR, Abucham J. Short- and Long-Term Efficacy of Combined Cabergoline and Octreotide Treatment in Controlling IGF-I Levels in Acromegaly. Neuroendocrinology. 2010;92(2):120-7.","journal-title":"Neuroendocrinology"},{"issue":"2","key":"key20220526082755_B32","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1210\/jcem.82.2.3648","article-title":"Effect of different dopaminergic agents in the treatment of acromegaly","volume":"82","author":"Colao","year":"1997","unstructured":"Colao A, Ferone D, Marzullo P, Di Sarno A, Cerbone G, Sarnacchiaro F, et al. Effect of different dopaminergic agents in the treatment of acromegaly. J Clin Endocrinol Metab. 1997;82(2):518-23.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"key20220526082755_B33","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/j.1365-2265.1988.tb03695.x","article-title":"Long-lasting lowering of serum growth hormone and prolactin levels by single and repetitive cabergoline administration in dopamine-responsive acromegalic patients","volume":"29","author":"Ferrari","year":"1988","unstructured":"Ferrari C, Paracchi A, Romano C, Gerevini G, Boghen M, Barreca A, et al. Long-lasting lowering of serum growth hormone and prolactin levels by single and repetitive cabergoline administration in dopamine-responsive acromegalic patients. Clin Endocrinol (Oxf). 1988;29(5):467-76.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"key20220526082755_B34","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1507\/endocrj.EJ12-0272","article-title":"Efficacy of combined octreotide and cabergoline treatment in patients with acromegaly: a retrospective clinical study and review of the literature","volume":"60","author":"Suda","year":"2013","unstructured":"Suda K, Inoshita N, Iguchi G, Fukuoka H, Takahashi M, Nishizawa H, et al. Efficacy of combined octreotide and cabergoline treatment in patients with acromegaly: a retrospective clinical study and review of the literature. Endocr J. 2013;60(4):507-15.","journal-title":"Endocr J"},{"issue":"1","key":"key20220526082755_B35","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1159\/000218323","article-title":"Optimizing Medical Therapy of Acromegaly: Beneficial Effects of Cabergoline in Patients Uncontrolled with Long-Acting Release Octreotide","volume":"90","author":"Jallad","year":"2009","unstructured":"Jallad RS, Bronstein MD. Optimizing Medical Therapy of Acromegaly: Beneficial Effects of Cabergoline in Patients Uncontrolled with Long-Acting Release Octreotide. Neuroendocrinology. 2009;90(1):82-92.","journal-title":"Neuroendocrinology"},{"issue":"4","key":"key20220526082755_B36","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/j.1365-2265.2005.02329.x","article-title":"Re-evaluation of the efficacy of the association of cabergoline to somatostatin analogues in acromegalic patients","volume":"63","author":"Gatta","year":"2005","unstructured":"Gatta B, Hau DH, Catargi B, Roger P, Tabarin A. Re-evaluation of the efficacy of the association of cabergoline to somatostatin analogues in acromegalic patients. Clin Endocrinol (Oxf). 2005;63(4):477-8.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"key20220526082755_B37","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1365-2265.2004.02082.x","article-title":"Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status","volume":"61","author":"Cozzi","year":"2004","unstructured":"Cozzi R, Attanasio R, Lodrini S, Lasio G. Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status. Clin Endocrinol (Oxf). 2004;61(2):209-15.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"key20220526082755_B38","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1530\/eje.1.01888","article-title":"Effectiveness of adding dopamine agonist therapy to long-acting somatostatin analogues in the management of acromegaly","volume":"152","author":"Selvarajah","year":"2005","unstructured":"Selvarajah D, Webster J, Ross R, Newell-Price J. Effectiveness of adding dopamine agonist therapy to long-acting somatostatin analogues in the management of acromegaly. Eur J Endocrinol. 2005;152(4):569-74.","journal-title":"Eur J Endocrinol"},{"issue":"12","key":"key20220526082755_B39","doi-asserted-by":"crossref","first-page":"4598","DOI":"10.1210\/jc.2007-1234","article-title":"Long-Term Efficacy and Safety of Combined Treatment of Somatostatin Analogs and Pegvisomant in Acromegaly","volume":"92","author":"Neggers","year":"2007","unstructured":"Neggers SJ, van Aken MO, Janssen JA, Feelders RA, de Herder WW, van der Lely AJ. Long-Term Efficacy and Safety of Combined Treatment of Somatostatin Analogs and Pegvisomant in Acromegaly. J Clin Endocrinol Metab. 2007;92(12):4598-601.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"key20220526082755_B40","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/cen.13595","article-title":"Treatment escape reduces the effectiveness of cabergoline during long-term treatment of acromegaly in monotherapy or in association with first-generation somatostatin receptor ligands","volume":"88","author":"Kasuki","year":"2018","unstructured":"Kasuki L, Dalmolin MD, Wildemberg LE, Gadelha MR. Treatment escape reduces the effectiveness of cabergoline during long-term treatment of acromegaly in monotherapy or in association with first-generation somatostatin receptor ligands. Clin Endocrinol (Oxf). 2018;88(6):889-95.","journal-title":"Clin Endocrinol (Oxf)"}],"container-title":["Archives of Endocrinology and Metabolism"],"original-title":[],"language":"en","deposited":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T07:12:16Z","timestamp":1700637136000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aem-sbem.com\/article\/efficacy-of-cabergoline-add-on-therapy-in-patients-with-acromegaly-resistance-to-somatostatin-analogs-treatment-and-the-review-of-literature\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,25]]},"references-count":40,"alternative-id":["10.20945\/2359-3997000000481"],"URL":"https:\/\/doi.org\/10.20945\/2359-3997000000481","relation":{},"ISSN":["2359-3997","2359-4292"],"issn-type":[{"type":"print","value":"2359-3997"},{"type":"electronic","value":"2359-4292"}],"subject":[],"published":{"date-parts":[[2022,5,25]]}}}